5-[4-(5-hydroxy-1,4,6,7-tetramethyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione | 185428-23-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 5-[4-(5-hydroxy-1,4,6,7-tetramethyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
• 英文别名: 5-[4-(5-Hydroxy-1,4,6,7-tetramethylbenzimidazol-2-ylmethoxy)-benzyl]-thiazolidine-2,4-dione；5-[4-(5-Hydroxy-1,4,6,7-tetramethylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione；5-[[4-[(5-hydroxy-1,4,6,7-tetramethylbenzimidazol-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
• CAS: 185428-23-3
• 化学式: C₂₂H₂₃N₃O₄S
• 分子量: 425.508
• InChiKey: MXSISWXKZWCHRT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-[4-(5-hydroxy-1,4,6,7-tetramethyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione 在 sodium chloride 、 乙酸酐 作用下， 生成 5-[4-(5-acetoxy-1,4,6,7-tetramethyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
  参考文献：
  名称：

  Benzimidazole derivatives, their preparation and their therapeutic use

  摘要：

  式(I)的化合物：##STR1##其中：X代表可选择取代的苯并咪唑基团；Y代表氧或硫原子；Z代表2,4-二氧代噻唑啉-5-基甲基、2,4-二氧代噻唑啉-5-基甲基、2,4-二氧代噻唑啉-5-基甲基、3,5-二氧代噻唑啉-2-基甲基或N-羟基脲基甲基基团；R代表氢、烷基、烷氧基、卤素、羟基、硝基、氨基或芳基烷基；m为1到5的整数；对于治疗和/或预防多种疾病，包括高脂血症、高血糖症、肥胖、糖耐量受损（IGT）、胰岛素抵抗和糖尿病并发症具有有价值的活性。

  公开号：

  US05886014A1
• 作为产物：
  描述：

  1,4-二氧六环 、 5-(4-methoxycarbonylmethyloxybenzyl)thiazolidine-2,4-dione 、 4-acetoxy-N-methyl-3,5,6-trimethyl-1,2-phenylenediamine 在 concentrated aqueous hydrochloric acid 、 sodium chloride 作用下， 以 四氢呋喃 、 ice-water 、 乙醚 、 乙酸乙酯 为溶剂， 生成 5-[4-(5-hydroxy-1,4,6,7-tetramethyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
  参考文献：
  名称：

  Benzimidazole derivatives, their preparation and their therapeutic use

  摘要：

  式(I)的化合物：##STR1##其中：X代表可选择取代的苯并咪唑基团；Y代表氧或硫原子；Z代表2,4-二氧代噻唑啉-5-基甲基、2,4-二氧代噻唑啉-5-基甲基、2,4-二氧代噻唑啉-5-基甲基、3,5-二氧代噻唑啉-2-基甲基或N-羟基脲基甲基基团；R代表氢、烷基、烷氧基、卤素、羟基、硝基、氨基或芳基烷基；m为1到5的整数；对于治疗和/或预防多种疾病，包括高脂血症、高血糖症、肥胖、糖耐量受损（IGT）、胰岛素抵抗和糖尿病并发症具有有价值的活性。

  公开号：

  US05886014A1

文献信息

• Therapeutic and prophylactic agents for neoplasms
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20020137776A1

  公开（公告）日：2002-09-26

  This invention relates to therapeutic and prophylactic agents for neoplasms which comprise a fused heterocyclic compound or a pharmaceutically acceptable salt thereof as an active ingredient; to the use of such a compound in the preparation of a medicament for the treatment and prevention of neoplasms; and to a method for treatment and prevention of neoplasms which comprises administering a pharmaceutically effective amount of such a compound to a warm-blooded animal (preferably a human).

  本发明涉及治疗和预防肿瘤的治疗剂和预防剂，其包括融合的杂环化合物或其药学上可接受的盐作为活性成分；使用这种化合物制备治疗和预防肿瘤的药物；以及一种治疗和预防肿瘤的方法，其中将这种化合物的药学有效量注射到温血动物（最好是人类）中。
• Treatment of arteriosclerosis and xanthoma
  申请人：Sankyo Company, Limited

  公开号：US06159997A1

  公开（公告）日：2000-12-12

  A combination of one or more HMG-CoA reductase inhibitors (for example pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin or atorvastatin) with one or more insulin sensitizers (for example troglitazone, pioglitazone, englitazone, BRL-49653, 5-(4-2-[1-(4-2'-pyridylphenyl)ethylideneaminooxy]ethoxy}benzyl)thiazolidi ne-2,4-dione, 5-4-(5-methoxy-3-methylimidazo[5,4-b]pyridin-2-ylmethoxy)benzyl}thiazolid ine-2,4-dione or its hydrochloride, 5-[4-(6-methoxy-1-methylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-d ione, 5-[4-(1-methylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione and 5-[4-(5-hydroxy-1,4,6,7-tetramethylbenzimidazol-2-ylmethoxy)benzyl]thiazol idine-2,4-dione) exhibits a synergistic effect and is significantly better at preventing and/or treating arteriosclerosis and/or xanthoma than is either of the components of the combination alone.

  一种将一种或多种HMG-CoA还原酶抑制剂（例如普伐他汀、洛伐他汀、辛伐他汀、氟伐他汀、利伐他汀或阿托伐他汀）与一种或多种胰岛素敏感剂（例如曲格列酮、派格列酮、恩格列酮、BRL-49653、5-（4-2-[1-(4-2'-吡啶基苯基)乙烯氨氧]乙氧基}苯基）噻唑烷-2,4-二酮、5-4-(5-甲氧基-3-甲基咪唑[5,4-b]吡啶-2-基甲氧基)苯基}噻唑烷-2,4-二酮或其盐酸盐、5-[4-(6-甲氧基-1-甲基苯并咪唑-2-基甲氧基)苯基]噻唑烷-2,4-二酮、5-[4-(1-甲基苯并咪唑-2-基甲氧基)苯基]噻唑烷-2,4-二酮和5-[4-(5-羟基-1,4,6,7-四甲基苯并咪唑-2-基甲氧基)苯基]噻唑烷-2,4-二酮）的组合展现出协同作用，并且在预防和/或治疗动脉粥样硬化和/或黄色瘤方面显著优于单独使用组合的任何成分。
• Synergistic combination comprising an insulin sensitizer and a HMG-CoA reductase inhibitor for treating arteriosclerosis
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0753298A1

  公开（公告）日：1997-01-15

  A combination of one or more HMG-CoA reductase inhibitors (for example pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin or atorvastatin) with one or more insulin sensitizers (for example troglitazone, pioglitazone, englitazone, BRL-49653, 5-(4-2-[1-(4-2'-pyridylphenyl)ethylideneaminooxy]-ethoxy}benzyl}thiazolidine-2,4-dione, 5-4-(5-methoxy-3-methylimidazo[5,4-b]pyridin-2-yl-methoxy)benzyl}thiazolidine-2,4-dione or its hydrochloride, 5-[4-(6-methoxy-1-methylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione, 5-[4-(1-methylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione and 5-[4-(5-hydroxy-1,4,6,7-tetramethylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione) exhibits a synergistic effect and is significantly better at preventing and/or treating arteriosclerosis and/or xanthoma than is either of the components of the combination alone.

  一种或多种 HMG-CoA 还原酶抑制剂（例如普伐他汀、洛伐他汀、辛伐他汀、氟伐他汀、利伐他汀或阿托伐他汀）与一种或多种胰岛素增敏剂（例如曲格列 酮、吡格列酮、英格列酮、BRL-49653、5-(4-2-[1-(4-2'-吡啶基苯基)亚乙基氨基氧基]-乙氧基}苄基）的复方制剂、恩格列酮、BRL-49653、5-(4-2-[1-(4-2'-吡啶基苯基)亚乙基氨基氧基]-乙氧基}苄基}噻唑烷-2,4-二酮、5-4-(5-甲氧基-3-甲基咪唑并[5,4-b]吡啶-2-基-甲氧基)苄基}噻唑烷-2,4-二酮或其盐酸盐、5-[4-(6-甲氧基-1-甲基苯并咪唑-2-基甲氧基)苄基]噻唑烷-2,4-二酮、5-[4-(1-甲基苯并咪唑-2-基甲氧基)苄基]噻唑烷-2,4-二酮和 5-[4-(5-羟基-1,4,6,7-四甲基苯并咪唑-2-基甲氧基)苄基]噻唑烷-2、4-二酮）产生协同效应，在预防和/或治疗动脉硬化和/或黄疽方面的效果明显优于单独使用组合中的任何一种成分。
• Treatment and prophylaxis of pancreatitis
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0796618A1

  公开（公告）日：1997-09-24

  Insulin sensitizers, especially thiazolidinedione compounds, such as troglitazone, are useful for the treatment and prevention of pancreatitis.

  胰岛素增敏剂，尤其是噻唑烷二酮化合物，如曲格列酮，可用于治疗和预防胰腺炎。
• Composition for use in the treatment and prevention of hyperuricemia
  申请人：Sankyo Company Limited

  公开号：EP0919232A1

  公开（公告）日：1999-06-02

  Insulin sensitivity enhancers, such as troglitazone, have the ability to treat and/or prevent hyperuricemia and may thus be used for the therapy or prophylaxis of such diseases as gout, urinary calculus, hyperuricemic nephropathy and Lesch-Nyhan syndrome.

  曲格列酮等胰岛素敏感性增强剂具有治疗和/或预防高尿酸血症的能力，因此可用于痛风、尿路结石、高尿酸血症肾病和莱希-尼汉综合征等疾病的治疗或预防。